20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
Cancer deaths are reduced yearly, but the number of cancer patients increases. This is because cancer prevention occurs through early diagnosis that prevents death from cancer but not the onset of the disease. To reduce the incidence of cancer, it is necessary to identify and treat the prodromal conditions of the disease as has been done to prevent cardiovascular diseases. Heart attacks have been reduced by 40% in 30 years because the monitoring of driver/prodromal conditions has been included in the prevention routine, which are hypercholesterolemia, hypertension, etc. The pathophysiological conditions that are the drivers of cancer are genomic instability, chronic inflammation, intestinal dysbiosis, and intestinal bacterial flora (microbiome), but none of these are investigated and managed regularly. Bioscience’s revolutionary testing methodology – HELIXAFE – focuses on detecting solid tumour driver conditions. The Company has identified 4 different driver conditions of solid tumours and has developed tests to analyse and monitor each condition. Pre-symptomatic detection has distinct advantages, as tumour drivers can always be cured, whereas the same does not apply to tumour treatment.
Bioscience Genomics is based on genomic technology for Cancer Driver Interceptions using cfDNA and circulating fetal free DNA sequencing. Instead of detecting early-stage cancer, Bioscience Genomics intercepts the cancer driver conditions before they appear.
The cancer driver conditions are silent and asymptomatic, do not express a pathological condition and take 5-15 years to develop a tumour.
Genetic instability is the main driver because it is the consequence of the progressive accumulation of somatic (acquired) mutations in DNA that occurs when tumour suppressor genes interrupt their function of repairing the damage that the DNA itself undergoes. In fact, DNA receives several thousand daily lesions that are repaired by tumour suppressor genes. Somatic mutations are formed if these genes stop working and no longer repair the damage.
Bioscience has patented the algorithm that detects the progressive accumulation of somatic mutations that indicate the inactivity of tumour suppressor genes and, therefore, the prodromal condition of the development of solid tumours. This is done by sequencing the circulating free DNA obtained from a simple blood sample. The other driver conditions of the development of solid tumours that Bioscience analyse are a) level of systemic inflammatory condition, b) balance of the immune system, and c) balance of the intestinal bacterial flora.
The analysis of the driver conditions of cancer development will also be extended to mitochondrial toxicity and dysfunction once the normality index, one of the targets of the validation clinical study that will be funded, is validated.
